Federated Hermes Inc. Has $1.45 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Federated Hermes Inc. has reduced its position in United Therapeutics Corporation by 33.4%, now owning 4,716 shares valued at approximately $1.45 million.
• Multiple analysts have adjusted their target prices for United Therapeutics, with Wells Fargo lowering it from $314 to $295 and JPMorgan from $350 to $330, indicating mixed sentiments around the stock's performance.
• Insiders at United Therapeutics have sold a total of 70,681 shares worth over $21 million in the last quarter, suggesting significant shifts in insider confidence.

Federated Hermes Inc. decreased its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 33.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,716 shares of the biotechnology company's stock after selling 2,362 shares during the quarter. Federated Hermes Inc.'s holdings in United Therapeutics were worth $1,454,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC lifted its holdings in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after buying an additional 393,777 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new position in United Therapeutics during the first quarter worth $101,354,000. GAMMA Investing LLC raised its stake in United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after purchasing an additional 221,202 shares during the last quarter. Northern Trust Corp boosted its holdings in United Therapeutics by 29.1% in the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock valued at $172,487,000 after purchasing an additional 110,298 shares during the period. Finally, AustralianSuper Pty Ltd boosted its holdings in United Therapeutics by 49.0% in the 1st quarter. AustralianSuper Pty Ltd now owns 282,739 shares of the biotechnology company's stock valued at $87,160,000 after purchasing an additional 92,959 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Richard Giltner sold 3,036 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the sale, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,681 shares of company stock worth $21,318,359. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Down 1.0%

United Therapeutics stock traded down $2.99 during mid-day trading on Thursday, hitting $299.42. 520,163 shares of the company were exchanged, compared to its average volume of 601,453. The company has a market capitalization of $13.51 billion, a PE ratio of 11.69, a price-to-earnings-growth ratio of 4.58 and a beta of 0.57. The business has a fifty day moving average of $296.94 and a 200 day moving average of $311.89. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $5.85 earnings per share. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on UTHR shares. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Cantor Fitzgerald initiated coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target for the company. Morgan Stanley reduced their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Finally, HC Wainwright set a $400.00 target price on United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $379.69.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.